(Q35004491)

English

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate (English)

1 reference

Europe PubMed Central

5 August 2017

1 reference

based on heuristic

inferred from title

zoledronic acid

1 reference

based on heuristic

inferred from title

3

object named as

Fred Saad

1 reference

Europe PubMed Central

5 August 2017

author name string

Allan Lipton

1

1 reference

Europe PubMed Central

5 August 2017

E Small

2

1 reference

Europe PubMed Central

5 August 2017

D Gleason

4

1 reference

Europe PubMed Central

5 August 2017

David Gordon

5

1 reference

Europe PubMed Central

5 August 2017

M Smith

6

1 reference

Europe PubMed Central

5 August 2017

Lee Rosen

7

1 reference

Europe PubMed Central

5 August 2017

M Ortu Kowalski

8

1 reference

Europe PubMed Central

5 August 2017

Dirk Reitsma

9

1 reference

Europe PubMed Central

5 August 2017

John Seaman

10

1 reference

Europe PubMed Central

5 August 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

5 August 2017

Cancer Investigation

1 reference

Europe PubMed Central

5 August 2017

20 Suppl 2

1 reference

Europe PubMed Central

5 August 2017

45-54

1 reference

Europe PubMed Central

5 August 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Spread of prostatic cancer to bone

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Stimulation of bone formation in vitro and in rodents by statins

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Treatment of painful prostatic bone metastases with oral etidronate disodium

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014886

21 January 2018

Identifiers

10.1081/CNV-120014886

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35004491&oldid=1663263077"